Published in J Virol on November 01, 2001
West Nile virus and its emergence in the United States of America. Vet Res (2010) 1.56
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol (2004) 1.50
E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol (2008) 1.25
Genetic determinants of Sindbis virus mosquito infection are associated with a highly conserved alphavirus and flavivirus envelope sequence. J Virol (2007) 1.03
Characterization of a small plaque variant of West Nile virus isolated in New York in 2000. Virology (2007) 0.99
Neuroadapted yellow fever virus 17D: determinants in the envelope protein govern neuroinvasiveness for SCID mice. J Virol (2003) 0.90
Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J Virol (2008) 0.79
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science (1985) 8.54
Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol (1989) 4.46
Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology (1994) 3.82
Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol (1995) 3.67
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
New mouse model for dengue virus vaccine testing. J Virol (1999) 3.18
Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol (1999) 2.87
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus. J Virol (1996) 2.33
Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci U S A (1987) 2.26
Spontaneous and engineered deletions in the 3' noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus. J Virol (1998) 2.11
Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol (1999) 1.94
Mutagenesis of the N-linked glycosylation sites of the yellow fever virus NS1 protein: effects on virus replication and mouse neurovirulence. Virology (1996) 1.87
The molecular basis of virulence of the encephalitogenic flaviviruses. J Gen Virol (1997) 1.85
Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch Virol (1994) 1.80
Genetic determinants of dengue type 4 virus neurovirulence for mice. J Virol (1993) 1.78
Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol (2000) 1.77
Apoptosis in the mouse central nervous system in response to infection with mouse-neurovirulent dengue viruses. J Virol (1998) 1.73
Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J Virol (1993) 1.72
Role of macrophages and antibody in resistance of mice against yellow fever virus. J Immunol (1971) 1.71
Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice. Virology (1992) 1.56
Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J Virol (2000) 1.56
Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis (1995) 1.46
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol (1995) 1.44
Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence. Virology (1990) 1.41
Variation in virulence for mice and rhesus monkeys among St. Louis encephalitis virus strains of different origin. Am J Trop Med Hyg (1980) 1.38
Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology (1999) 1.35
Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence. J Virol (1998) 1.34
Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol (2001) 1.32
Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. Virology (1998) 1.30
Molecular analysis of neurovirulent strains of Sindbis virus that evolve during persistent infection of scid mice. J Virol (1993) 1.28
Secondary structure of the 3'-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development. J Gen Virol (1997) 1.28
Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology (1998) 1.28
Infectious cDNA clones of Langat tick-borne flavivirus that differ from their parent in peripheral neurovirulence. Virology (2000) 1.21
Viral neuroinvasion and encephalitis induced by lipopolysaccharide and its mediators. J Exp Med (1992) 1.19
Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis (1994) 1.18
Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J Gen Virol (1996) 1.15
Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type 1 virus. Virology (2000) 1.11
The severity of murray valley encephalitis in mice is linked to neutrophil infiltration and inducible nitric oxide synthase activity in the central nervous system. J Virol (1999) 1.07
Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology (1997) 1.07
Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol (2000) 1.06
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology (1999) 1.03
Murray valley encephalitis virus envelope protein antigenic variants with altered hemagglutination properties and reduced neuroinvasiveness in mice. Virology (1995) 1.02
A novel model for the study of the therapy of flavivirus infections using the Modoc virus. Virology (2001) 1.02
Molecular differences between wild-type Japanese encephalitis virus strains of high and low mouse neuroinvasiveness. J Gen Virol (1996) 1.01
Comparison of neurovirulence of different strains of yellow fever virus in mice. J Gen Virol (1986) 1.00
The in vivo differentiation of strains of yellow fever virus in mice. J Gen Virol (1980) 1.00
A mouse-attenuated envelope protein variant of Murray Valley encephalitis virus with altered fusion activity. J Gen Virol (1996) 0.94
Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. J Gen Virol (1981) 0.91
Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J Gen Virol (1997) 0.87
Phenotypic analysis of yellow fever virus derived from complementary DNA. Am J Trop Med Hyg (1995) 0.84
Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice. J Infect Dis (1971) 0.79
Identification and characterization of membrane cofactor protein of human spermatozoa. J Immunol (1992) 1.05
Additional forms of human decay-accelerating factor (DAF). J Immunol (1987) 1.05
Complement receptors and regulatory proteins: immune adherence revisited and abuse by microorganisms. Clin Exp Immunol (1994) 0.83
Primary sequence of baboon CR1 demonstrates concerted evolution within the CR1 gene. Mol Immunol (1997) 0.75